TRIPHARM

TRIPHARM has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €221,293 and a net result of €19,829. Equity remains stable across the filed financial years (±1.4% per year). Its solvency ranks better than 50% of 10,686 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).